Global Amlodipine and Olmesartan Market Size By Type (5/20 mg Tablets, 10/20 mg Tablets), By Application (Hospital, Drug store), By Region, And Segment Forecasts, 2023 to 2032

The Global Amlodipine and Olmesartan Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.7 billion by 2031, growing at a CAGR of 7.1% during the forecast period from 2023 to 2031. Amlodipine and olmesartan are widely prescribed as a combination therapy for hypertension. This market’s growth is driven by the rising prevalence of cardiovascular diseases, the expanding geriatric population, and increasing awareness about combination drug therapies that enhance compliance and therapeutic outcomes.

Drivers:

1. Rising Incidence of Hypertension:

The growing global burden of high blood pressure, affecting over 1.2 billion people, is a significant driver. Amlodipine-olmesartan therapy provides effective blood pressure control with fewer side effects, which is driving its preference.

2. Geriatric Population Growth:

An aging population contributes to a higher prevalence of chronic diseases like hypertension, thus driving the demand for long-term antihypertensive treatments such as amlodipine and olmesartan.

3. Increased Awareness of Cardiovascular Health:

Healthcare initiatives and public awareness campaigns focused on managing blood pressure are increasing the uptake of combination therapies, supporting market growth.

Restraints:

1. Generic Drug Competition:

Patent expirations have led to a surge in generic alternatives, which has intensified price competition and reduced the revenue margins for branded drugs.

2. Side Effects and Drug Interactions:

Adverse effects such as dizziness, hypotension, and potential kidney issues in some patient groups could hinder adoption, especially in populations with comorbidities.

Opportunity:

1. Expansion in Emerging Markets:

Rapid urbanization and lifestyle changes in Asia-Pacific, Latin America, and the Middle East are increasing hypertension prevalence, creating strong growth potential for combination therapies.

2. Formulation Innovation:

Development of fixed-dose combinations with extended-release or novel delivery systems can improve compliance and differentiate branded products from generics.

Market by System Type Insights:

Based on formulation type, the Fixed-Dose Combination Tablets segment held the largest market share in 2023. Patients and healthcare providers favor fixed-dose combinations of amlodipine and olmesartan due to the convenience of a single-pill regimen, leading to improved adherence and better clinical outcomes.

Market by End-use Insights:

By end use, the Retail Pharmacies segment dominated the global market in 2023, accounting for more than 55% of total revenue. Retail pharmacies are the primary distribution channel for hypertension medication, and growing consumer preference for over-the-counter and easy-access purchases supports this trend.

Market by Regional Insights:

North America led the market in 2023 due to a high prevalence of lifestyle-related cardiovascular diseases, strong healthcare infrastructure, and widespread adoption of fixed-dose combination therapies. However, Asia-Pacific is expected to grow at the fastest pace during the forecast period due to increasing diagnosis rates, improving access to healthcare, and government-led initiatives to combat chronic diseases.

Competitive Scenario:

Key players in the Global Amlodipine and Olmesartan Market include:

Daiichi Sankyo Company, Limited

Pfizer Inc.

Mylan N.V. (Viatris)

Teva Pharmaceuticals

Lupin Limited

Novartis AG

Torrent Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

These companies focus on expanding their generics portfolio, securing regulatory approvals, and forming strategic partnerships to enhance their geographic reach and product offerings.

Scope of Work – Global Amlodipine and Olmesartan Market

Key Market Developments:

2023: Daiichi Sankyo expanded its manufacturing facility in Japan to meet growing global demand for hypertension combination drugs.

2024: Mylan received FDA approval for a generic version of amlodipine-olmesartan medoxomil combination, enhancing its U.S. portfolio.

2025: Sun Pharma launched an extended-release formulation of amlodipine and olmesartan for improved patient compliance in India.

FAQs:

1) What is the current market size of the Global Amlodipine and Olmesartan Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Amlodipine and Olmesartan Market?

The primary growth driver is the rising prevalence of hypertension globally.

3) Which is the largest region during the forecast period in the Global Amlodipine and Olmesartan Market?

North America is the largest region in terms of market share, while Asia-Pacific is the fastest growing.

4) Which segment accounted for the largest market share in the Global Amlodipine and Olmesartan Market?

The Fixed-Dose Combination Tablets segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Amlodipine and Olmesartan Market?

Key players include Daiichi Sankyo, Pfizer, Mylan (Viatris), Teva, Lupin, Novartis, and Sun Pharma.